Search

Progressive myoclonus epilepsy of Lafora type (LD, MIM 254780) is a fatal autosomal recessive disorder characterized by the presence of progressive neurological deterioration, myoclonus, epilepsy and polyglucosan intracellular inclusion bodies, called Lafora bodies. Lafora bodies resemble glycogen with reduced branching, suggesting an alteration in glycogen metabolism. Linkage analysis and homozygosity mapping localized EPM2A, a major gene for LD, to chromosome 6q24. EPM2A encodes a protein of 331 amino acids (named laforin) with two domains, a dual-specificity phosphatase domain and a carbohydrate binding domain. Here we show that, in addition, laforin interacts with itself and with the glycogen targeting regulatory subunit R5 of protein phosphatase 1 (PP1). R5 is the human homolog of the murine Protein Targeting to Glycogen, a protein that also acts as a molecular scaffold assembling PP1 with its substrate, glycogen synthase, at the intracellular glycogen particles. The laforin–R5 interaction was confirmed by pull-down and co-localization experiments. Full-length laforin is required for the interaction. However, a minimal central region of R5 (amino acids 116–238), including the binding sites for glycogen and for glycogen synthase, is sufficient to interact with laforin. Point-mutagenesis of the glycogen synthase-binding site completely blocked the interaction with laforin. The majority of the EPM2A missense mutations found in LD patients result in lack of phosphatase activity, absence of binding to glycogen and lack of interaction with R5. Interestingly, we have found that the LD-associated EPM2A missense mutation G240S has no effect on the phosphatase or glycogen binding activities of laforin but disrupts the interaction with R5, suggesting that binding to R5 is critical for the laforin function. These results place laforin in the context of a multiprotein complex associated with intracellular glycogen particles, reinforcing the concept that laforin is involved, Ministerio de Ciencia y Tecnología, Instituto de Salud Carlos III, Asociación Lafora España, Depto. de Bioquímica y Biología Molecular, Fac. de Ciencias Químicas, TRUE, pub

Lafora disease is a progressive myoclonus epilepsy caused by mutations in the EPM2A gene encoding laforin or in the EPM2B gene encoding malin. It is characterized by the presence of polyglucosan intracellular inclusion bodies (Lafora bodies) in brain and other tissues. Targeted disruption of Epm2a or Epm2b genes in mice produced widespread neuronal degeneration and accumulation of Lafora bodies in neuronal and nonneuronal tissues. Here we analyzed the neurologic alterations produced by disruption of the laforin gene in Epm2a−/− mice and compared them to those in malin-deficient mice. Both Epm2a−/− and Epm2b−/− mice showed altered motor activity, impaired motor coordination, abnormal hind limb clasping, and episodic memory deficits. Epm2a−/− mice also had tonic-clonic seizures, whereas both Epm2a−/− and Epm2b−/− mice had spontaneous single spikes, spike-wave, polyspikes, and polyspike-wave complexes with correlated myoclonic jerks. Neurologic alterations observed in the mutants were comparable and correlated with the accumulation of abundant Lafora bodies in the cerebral cortex, the hippocampus, the basal ganglia, the cerebellum, and the brainstem, suggesting that these inclusions could cause cognitive and behavioral deterioration. Thus, both Epm2a−/− and Epm2b−/− mice exhibit many pathologic aspects seen in patients with Lafora disease and may be valuable for the study of this disorder

Lafora progressive myoclonus epilepsy (LD) is a fatal autosomal recessive neurodegenerative disorder characterized by the presence of glycogen-like intracellular inclusions called Lafora bodies. LD is caused by mutations in two genes, EPM2A and EPM2B, encoding respectively laforin, a dual-specificity protein phosphatase, and malin, an E3 ubiquitin ligase. Previously, we and others have suggested that the interactions between laforin and PTG (a regulatory subunit of type 1 protein phosphatase) and between laforin and malin are critical in the pathogenesis of LD. Here, we show that the laforin–malin complex downregulates PTG-induced glycogen synthesis in FTO2B hepatoma cells through a mechanism involving ubiquitination and degradation of PTG. Furthermore, we demonstrate that the interaction between laforin and malin is a regulated process that is modulated by the AMP-activated protein kinase (AMPK). These findings provide further insights into the critical role of the laforin–malin complex in the control of glycogen metabolism and unravel a novel link between the energy sensor AMPK and glycogen metabolism. These data advance our understanding of the functional role of laforin and malin, which hopefully will facilitate the development of appropriate LD therapies

Background: Lafora disease (LD; progressive myoclonus epilepsy type 2; EPM2) is an autosomal recessive disorder caused by mutations in the EPM2A and EPM2B genes. LD is characterized by the presence of strongly PAS-positive intracellular inclusions (Lafora bodies) in several tissues. Glycogen storage disease type IV (GSD-IV; Andersen disease) is an autosomal recessive disorder characterized by cirrhosis leading to severe liver failure. GSD-IV has been associated with mutations in the glycogen branching enzyme gene (GBE). Histopathologic changes of the liver in both diseases show an identical appearance, although cirrhosis has never been described in patients with LD. We report a LD family in which the proband presented severe liver failure at onset of the disease. Methods: Clinical histories, physical and neurologic examination, laboratory tests, EEGs, MRI of the brain, and liver or axillary skin biopsies were performed in the two affected siblings. The diagnosis was confirmed by molecular genetic analysis of the EPM2A, EPM2B, and GBE genes and loci. Results: During the first decade of life, abnormalities in liver function tests were detected in the two affected siblings. The proband's liver dysfunction was severe enough to require liver transplantation. Subsequently, both sibs developed LD. Mutation analysis of EPM2A revealed a homozygous Arg241stop mutation in both patients. Conclusions: This is the first description of severe hepatic dysfunction as the initial clinical manifestation of LD. The phenotypic differences between the two affected siblings suggest that modifier genes must condition clinical expression of the disease outside the CNS

Objective: To study EPM2B gene mutations and genotype-phenotype correlations in patients with Lafora disease. Methods: The authors performed a clinical and mutational analysis of 25 patients, from 23 families, diagnosed with Lafora disease who had not shown mutations in the EPM2A gene. Results: The authors identified 18 mutations in EPM2B, including 12 novel mutations: 4 nonsense mutations (R265X, C26X, W219X, and E67X), a 6-base pair (bp) microdeletion resulting in a two amino acid deletion (V294_K295del), a 4-bp insertion resulting in a frameshift mutation (S339fs12), and 6 missense mutations (D308A, I198N, C68Y, E67Q, P264H, and D233A). In our data set of 77 families with Lafora disease, 54 (70.1%) tested probands have mutations in EPM2A, 21 (27.3%) in EPM2B, and 2 (2.6%) have no mutations in either gene. The course of the disease was longer in patients with EPM2B mutations vs patients with EPM2A mutations. Conclusions: Genetic allelic heterogeneity is present in Lafora disease associated with mutations in EPM2B. Patients with mutations in EPM2A and EPM2B express similar clinical manifestation, although patients with EPM2B-associated Lafora disease seem to have a slightly milder clinical course. The lack of mutations in EPM2A and EPM2B in two families could be because of the presence of mutations in noncoding, nontested regions or the existence of an additional gene associated with Lafora disease.

The process of incorporation of pyridine in the nanostructured tunnels of sepiolite was studied in detail, using various complementary characterization techniques, microporosimetry, thermal gravimetric analysis, FTIR, and multinuclear solid-state NMR. It is demonstrated that a remarkable nanohybrid material, SEP-PYR, is formed through the direct coordination of pyridine to the edge Mg(II) sites of the tunnels. This material is formed at temperatures above 140 °C when the sepiolite tunnels are dehydrated and the pyridine molecules are trapped in the tunnels. In a first step toward the formation of SEP-PYR, the pyridine molecules were incorporated at room temperature in the tunnels, by exposing sepiolite to pyridine vapors. The incorporated pyridine molecules are H-bound to the structural water molecules coordinated to the edge Mg(II) cations. In a second step, upon heating to 140 °C, approximately 50% of the pyridine is lost, together with most of the structural water coordinated to Mg(II). This event is accompanied by direct coordination of the remaining pyridine molecules in the tunnels to the edge Mg(II) ions of the octahedral sheets, resulting in a material with a structure similar to the parent sepiolite, but with pyridine molecules coordinated to the Mg(II) edge cations. This material is stable up to 450 °C. At this temperature, the coordinated pyridine molecules escape from the tunnels, resulting in a collapsed sepiolite structure.

The present work is related to the use of sepiolite for the stabilization of certain photo or thermolabile herbicides by their adsorption on sepiolite-modified materials that act as organo-inorganic supports of the pesticides. The study demonstrates that formulations based on sepiolite containing a cationic dye (thioflavine-T (TFT)) are very effective in the stabilization of a photolabile herbicide (trifluralin (TF)). A modification of the hydrophilic character of the sepiolite surface by adsorption of cationic surfactants enhances the adsorption on the mineral substrate of non-polar pesticides, such as the herbicides alachlor (ACH) or metolachlor (MCH), thus contributing to the decrease of their losses by volatilization.

Progressive myoclonus epilepsy of the Lafora type or Lafora disease (EPM2; McKusick no. 254780) is an autosomal recessive disorder characterized by epilepsy, myoclonus, progressive neurological deterioration and glycogen-like intracellular inclusion bodies (Lafora bodies). A gene for EPM2 previously has been mapped to chromosome 6q23-q25 using linkage analysis and homozygosity mapping. Here we report the positional cloning of the 6q EPM2 gene. A microdeletion within the EPM2 critical region, present in homozygosis in an affected individual, was found to disrupt a novel gene encoding a putative protein tyrosine phosphatase (PTPase). The gene, denoted EPM2, presents alternative splicing in the 5' and 3' end regions. Mutational analysis revealed that EPM2 patients are homozygous for loss-of-function mutations in EPM2. These findings suggest that Lafora disease results from the mutational inactivation of a PTPase activity that may be important in the control of glycogen metabolism.

Adsorption of neutral organic molecules and the monovalent organic cations methylene blue (MB) and crystal violet (CV) to sepiolite was determined experimentally and investigated by an adsorption model. The largest amounts of MB and CV adsorbed were about 4-fold of the cation exchange capacity (CEC) of sepiolite. Consequently, it was proposed that most of the above described adsorption was to neutral sites of the clay. The adsorption model considered combines the Gouy-Chapman solution and specific binding in a closed system. The model was extended by allowing cation adsorption to neutral sites of the clay, in addition to adsorption to negatively charged sites and adsorption to neutral complexes formed from 1 cation adsorbed to a negative surface site. The amount of available neutral sites was determined from the adsorption of the neutral molecule Triton-X 100 (TX100). The model could adequately simulate the adsorption of the neutral molecules TX100 and crown ether 15-crown-5 (15C5) as well as the organic cations. Due to aggregation of MB molecules in solution, their adsorption was somewhat less than that of CV at the larger added concentrations. A consideration of the molecular dimensions of TX100, MB and CV suggested that their adsorption was mostly to external sites of the clay and that their entry to the sepiolite channels was largely excluded. This interpretation is supported by infrared spectroscopy (IR) measurements, which show large perturbations of the peak corresponding to vibrations of external Si-OH groups of the clay and confirm complete occupancy of external sites by MB and CV.

Intercalation of crown ethers (15-crown-5 and 18-crown-6) in NH4 +-montmorillonite produces strong modifications in the infrared spectrum of the ammonium ions located in the interlamellar space of the phyllosilicate. These modifications are explained as a result of the lowering of the Td symmetry, characteristic of free NH4 + cations as a consequence of their interaction with oxygen atoms of the intercalated macrocyclic molecules.